Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting ...

Fintel reports that on March 11, 2025, Leerink Partners downgraded their outlook for 2seventy bio (NasdaqGS:TSVT) from ...

Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of ...

Shares of 2seventy bio, Inc. (NASDAQ:TSVT – Get Free Report) have received a consensus rating of “Hold” from the eight ...

Leerink Partners 2025 Global Healthcare Conference Call March 12, 2025 11:20 AM ETCompany ParticipantsRoland Chen ...

Equities research analysts at William Blair issued their FY2029 earnings per share (EPS) estimates for shares of Genmab A/S ...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...

In a report released today, Daina Graybosch from Leerink Partners downgraded 2seventy bio (TSVT – Research Report) to a Hold, with a price ...

Leerink downgraded 2seventy Bio (TSVT) (TVST) to Market Perform from Outperform with a price target of $5, down from $9, to reflect the pending ...

On Tuesday, 11 March 2025, MacroGenics (NASDAQ: MGNX) presented at Leerink’s Global Healthcare Conference 2025. The company showcased its robust pipeline of cancer therapeutics and strategic ...

Dave Reisinger, Cover Diversified Biopharmaceuticals, Leerink Partners: All righty. Great. Well, welcome, everyone. My name is Dave Reisinger. For those of you who don’t know me, I cover ...